key: cord-0920646-drgrr23k
authors: Huang, Ying; Xie, Changming; Chen, Xiaoke; Hong, Qianhui; Huang, Hui
title: Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?
date: 2020-06-04
journal: Pharmacol Res
DOI: 10.1016/j.phrs.2020.104959
sha: cd679350a339d2e1e8e5145dd75cabf5d7f4b315
doc_id: 920646
cord_uid: drgrr23k

nan

However, a more aggressive opinion was reported by Juan M Saavedra and colleagues that ARBs can be included as additional therapy for COVID-19 patients without hypertension. Theoretically, the decrease of ACE2, caused by SARS-CoV-2 infection, would break the balance between ACE and ACE2. As a result, Renin-Angiotensin-Aldosterone system (RAAS) was positively regulated and angiotensin II type 1 receptor was over stimulated, which may further cause inflammation activation, endothelial injury, mitochondrial dysfunction and pulmonary capillary permeability increasing, followed by edema and acute lung failure. Besides, ARBs were reported to restore ACE2/Ang1−7/Mas axis, which bring RAAS back to balance. All these potential benefits make ARBs hopeful agents to prevent the progress of COVID-19, in the authors' opinion [2] .

Even this hypothesis makes sense to some degree and the alternation of RAAS was also [5] .

Taken together, we speculate that the change of RAS is just a concomitant symptom of COVID-19, instead of an important factor that facilitating infection. More clinic reports as well as meta-analyze and basic research are still in need before applying ACEIs/ ARBs in COVID-19 treatment.

We declare that we do not have any commercial or associative interest that represents a conflict of interest in connection with the work submitted. 

Angiotensin receptor blockers and COVID-19

Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury

Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19

Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19